If you have a question, Jim Cramer has an answer.
Should the "Mad Money" host not have an opinion on a stock when asked by a viewer, he always does his homework and will address the stock at a future date. On Friday, Cramer commented on some outstanding questions.
On Tuesday, viewer Renee in California asked about Cynosure. Last month, the company announced that it has received FDA 510(k) clearance to market the PicoSure laser workstation for the removal of tattoos and benign pigmented lesions. The company expects to sell PicoSure initially through its U.S. direct sales force to aesthetic dermatologists and plastic surgeons beginning in early 2013.
"Cynosure's device is exciting because it's the first real breakthrough in tattoo removal that we've seen the last 20 years," Cramer said, adding PicoSure can reduce the number of treatments needed for a tattoo removal by nearly 50 percent, at least according to the company. "That said, the stock doubled in 2012 and it's now trading at 30 times this year's earnings estimates, so the expectations are high. I would wait for a pullback, as the new sales opportunities already seem to be inked into Cynosure's stock price."
Meanwhile, viewer Justin in Illinois recently asked Cramer about medical billing services provider Accretive Health. In July, the Chicago-based company settled a lawsuit, which was brought by Minnesota Attorney General Lori Swanson in January 2012. It alleged that Accretive had violated state and federal health privacy laws through aggressive debt collection tactics, including having its management "imbedded" into the staff of Minnesota hospitals and managing hospital employees engaged in collections and patient registration.
Accretive must pay $2.5 million and stop all business operations in Minnesota within the next 90 days under the settlement. The money will partly be used to compensate patients, with the rest going to the state treasury. It's now barred from practicing in the state for at least two years, too.
Nevertheless, Cramer pointed out that medical billing services is now a "hot space" thanks to Obamacare – the health care reform bill, which President Barack Obama signed into law March 23, 2010. While he might consider buying Accretive shares on a pullback, he currently prefers healthcare service provider Athena Health.
Finally, viewer John in New Jersey recently asked about Just Energy Group, an utility that sells both natural gas and electricity. With natural gas trading at low levels, Cramer said Just Energy's customers are likely in no hurry to lock-in long term contracts. He's also concerned about the stock's 12.5 percent dividend yield.
"That's a serious red flag. Just Energy's cash flows are under pressure from the company's expansion initiatives and higher marketing expenses, so I think a dividend cut is definitely possible," Cramer said. "You should steer clear of this stock, no question."
Call Cramer: 1-800-743-CNBC
Questions for Cramer? firstname.lastname@example.org
Questions, comments, suggestions for the "Mad Money" website? email@example.com
Reuters contributed to this report